<VariationArchive VariationID="2127122" VariationName="NM_000116.5(TAFAZZIN):c.575del (p.Phe192fs)" VariationType="Deletion" Accession="VCV002127122" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-20" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2178435" VariationID="2127122">
      <GeneList>
        <Gene Symbol="TAFAZZIN" FullName="tafazzin, phospholipid-lysophospholipid transacylase" GeneID="6901" HGNC_ID="HGNC:11577" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq28</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="154411539" stop="154421726" display_start="154411539" display_stop="154421726" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="153639876" stop="153650064" display_start="153639876" display_stop="153650064" Strand="+" />
          </Location>
          <OMIM>300394</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000116.5(TAFAZZIN):c.575del (p.Phe192fs)</Name>
      <CanonicalSPDI>NC_000023.11:154419735:TTT:TT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq28</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="154419736" stop="154419736" display_start="154419736" display_stop="154419736" variantLength="1" positionVCF="154419735" referenceAlleleVCF="GT" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="153648075" stop="153648075" display_start="153648075" display_stop="153648075" variantLength="1" positionVCF="153648074" referenceAlleleVCF="GT" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>F162fs</ProteinChange>
      <ProteinChange>F192fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000116.5" sequenceAccession="NM_000116" sequenceVersion="5" change="c.575del" MANESelect="true">
            <Expression>NM_000116.5:c.575del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000107.1" sequenceAccession="NP_000107" sequenceVersion="1" change="p.Phe192fs">
            <Expression>NP_000107.1:p.Phe192fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001410698.1" sequenceAccession="NM_001410698" sequenceVersion="1" change="c.539delT">
            <Expression>NM_001410698.1:c.539delT</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001397627.1" sequenceAccession="NP_001397627" sequenceVersion="1" change="p.Phe180Serfs">
            <Expression>NP_001397627.1:p.Phe180Serfs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_181311.4" sequenceAccession="NM_181311" sequenceVersion="4" change="c.485del">
            <Expression>NM_181311.4:c.485del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_851828.1" sequenceAccession="NP_851828" sequenceVersion="1" change="p.Phe162fs">
            <Expression>NP_851828.1:p.Phe162fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_024048.3" sequenceAccession="NR_024048" sequenceVersion="3" change="n.896del">
            <Expression>NR_024048.3:n.896del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001303465.2" sequenceAccession="NM_001303465" sequenceVersion="2" change="c.595+115del">
            <Expression>NM_001303465.2:c.595+115del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_181312.4" sequenceAccession="NM_181312" sequenceVersion="4" change="c.541+115del">
            <Expression>NM_181312.4:c.541+115del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_181313.4" sequenceAccession="NM_181313" sequenceVersion="4" change="c.451+115del">
            <Expression>NM_181313.4:c.451+115del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.153648077del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.153648077del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.154419738del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.154419738del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009634.2" sequenceAccession="NG_009634" sequenceVersion="2" change="g.13204del">
            <Expression>NG_009634.2:g.13204del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_147842.1" sequenceAccession="NG_147842" sequenceVersion="1" change="g.251del">
            <Expression>NG_147842.1:g.251del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_131t1" sequenceAccession="LRG_131t1">
            <Expression>LRG_131t1:c.575del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_131p1" sequenceAccession="LRG_131p1" change="p.Phe192fs">
            <Expression>LRG_131p1:p.Phe192fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_131" sequenceAccession="LRG_131">
            <Expression>LRG_131:g.13204del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000116.5(TAFAZZIN):c.575del (p.Phe192fs) AND 3-Methylglutaconic aciduria type 2" Accession="RCV003052004" Version="2">
        <ClassifiedConditionList TraitSetID="3071">
          <ClassifiedCondition DB="MedGen" ID="C0574083">3-Methylglutaconic aciduria type 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-04-17" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-04-17" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16427346</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22382802</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23409742</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3071" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="487" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">3-methylglutaconicaciduria type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MGA type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cardioskeletal myopathy with neutropenia and abnormal mitochondria</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Barth syndrome</ElementValue>
                <XRef ID="MONDO:0010543" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">3-Methylglutaconic aciduria type 2</ElementValue>
                <XRef ID="Barth+Syndrome/744" DB="Genetic Alliance" />
                <XRef ID="297231002" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">BTHS</ElementValue>
                <XRef Type="MIM" ID="302060" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MGCA2</ElementValue>
                <XRef Type="MIM" ID="302060" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MGA2</ElementValue>
                <XRef Type="MIM" ID="302060" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5890" />
                <XRef ID="5890" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Barth syndrome is characterized in affected males by cardiomyopathy, neutropenia, skeletal myopathy, prepubertal growth delay, and distinctive facial gestalt (most evident in infancy); not all features may be present in a given affected male. Cardiomyopathy, which is almost always present before age five years, is typically dilated cardiomyopathy with or without endocardial fibroelastosis or left ventricular noncompaction; hypertrophic cardiomyopathy can also occur. Heart failure is a significant cause of morbidity and mortality; risk of arrhythmia and sudden death is increased. Neutropenia is most often associated with mouth ulcers, pneumonia, and sepsis. The nonprogressive myopathy predominantly affects the proximal muscles, and results in early motor delays. Prepubertal growth delay is followed by a postpubertal growth spurt with remarkable "catch-up" growth. Heterozygous females who have a normal karyotype are asymptomatic and have normal biochemical studies.</Attribute>
                <XRef ID="NBK247162" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301486</ID>
                <ID Source="BookShelf">NBK1309</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">25299040</ID>
                <ID Source="BookShelf">NBK247162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C5-OH.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C5-OH Acylcarnitine, Organic Acidemias, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C5-OH-Elevated.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Organic Acidemias: Elevated C5-OH, 2022</CitationText>
              </Citation>
              <XRef ID="111" DB="Orphanet" />
              <XRef ID="C0574083" DB="MedGen" />
              <XRef ID="MONDO:0010543" DB="MONDO" />
              <XRef Type="MIM" ID="302060" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="6034308" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="16431084|MedGen:C0574083" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003343025" DateUpdated="2024-02-20" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16427346</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22382802</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23409742</ID>
          </Citation>
          <Comment>This variant has not been reported in the literature in individuals affected with TAZ-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Phe192Serfs*8) in the TAZ gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TAZ are known to be pathogenic (PMID: 16427346, 22382802, 23409742). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TAFAZZIN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.153648075del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0574083" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="6034308" TraitType="Disease" MappingType="XRef" MappingValue="C0574083" MappingRef="MedGen">
        <MedGen CUI="C0574083" Name="3-Methylglutaconic aciduria type 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

